Literature DB >> 17372738

[Surgical treatments for retinal vein occlusion].

N Feltgen1, H Agostini, L Hansen.   

Abstract

The range of therapeutic options for the treatment of retinal vein occlusions has been decisively extended by three new surgical methods: radial optic neurotomy (RON) and retinal endovascular lysis (REVL) for central retinal vein occlusion, and arteriovenous dissection (AVD/sheathotomy) for branch retinal vein occlusion. None of those methods has been tested in randomised studies meeting the requirements of evidence-based medicine. It is therefore difficult to assess the relative values of the individual procedures and determine in what precise circumstances each is indicated. The difficulties are compounded further by the use of these techniques in association with new and promising intravitreally injected drugs (e.g. steroids and angioinhibitors), which makes it even more difficult to assess the real efficacy of the surgical methods. In this paper we discuss the three different surgical methods and try to evaluate their clinical benefit.

Entities:  

Mesh:

Year:  2007        PMID: 17372738     DOI: 10.1007/s00347-007-1508-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  39 in total

1.  Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases.

Authors:  E M Opremcak; R A Bruce; M D Lomeo; C D Ridenour; A D Letson; A J Rehmar
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Histopathologic findings after radial optic neurotomy in central retinal vein occlusion.

Authors:  Antje Vogel; Frank G Holz; Karin U Loeffler
Journal:  Am J Ophthalmol       Date:  2006-01       Impact factor: 5.258

3.  Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases.

Authors:  W R Green; C C Chan; G M Hutchins; J M Terry
Journal:  Retina       Date:  1981       Impact factor: 4.256

4.  Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults.

Authors:  Leon A Bynoe; Jeffrey N Weiss
Journal:  Am J Ophthalmol       Date:  2003-03       Impact factor: 5.258

5.  Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase.

Authors:  S S Hayreh; M R Klugman; M Beri; A E Kimura; P Podhajsky
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

6.  Surgical decompression of branch retinal vein occlusions.

Authors:  M D Osterloh; S Charles
Journal:  Arch Ophthalmol       Date:  1988-10

7.  Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein.

Authors:  J N Weiss
Journal:  Am J Ophthalmol       Date:  1998-07       Impact factor: 5.258

8.  Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion.

Authors:  L O Hattenbach; G Steinkamp; I Scharrer; C Ohrloff
Journal:  Ophthalmologica       Date:  1998       Impact factor: 3.250

9.  Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study.

Authors:  S Wolf; O Arend; B Bertram; A Remky; K Schulte; K J Wald; M Reim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-01       Impact factor: 3.117

10.  The natural course of central retinal vein occlusion.

Authors:  P M Quinlan; M J Elman; A K Bhatt; P Mardesich; C Enger
Journal:  Am J Ophthalmol       Date:  1990-08-15       Impact factor: 5.258

View more
  4 in total

1.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

Review 2.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

3.  [Retrospective case analysis of ophthalmological and systemic risk factors in patients with retinal vascular occlusion].

Authors:  C Klatt; K Purtskhvanidze; H Hasselbach; F Treumer; J Hillenkamp; J Roider
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

4.  Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.

Authors:  Thomas Bertelmann; Nicolas Feltgen; Martin Scheffler; Ulrich Hufenbach; Annette Wiedon; Helmut Wilhelm; Focke Ziemssen
Journal:  Health Qual Life Outcomes       Date:  2016-09-20       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.